PEDRITO M. NEPOMUCENO vs. PRESIDENT RODRIGO R. DUTERTE

The governing principle is that a writ of mandamus lies only to compel the performance of a ministerial duty, and it cannot be used to control discretionary acts of executive officials. Because Congress expressly waived the mandatory clinical trial and public bidding requirements for COVID-19 vaccine procurement through emergency legislation, the respondents’ procurement and authorization of the Sinovac vaccine constituted lawful exercises of delegated discretion. Furthermore, an incumbent President enjoys absolute immunity from suit during tenure, and direct invocation of the Supreme Court’s original jurisdiction is improper when the petition raises factual questions without falling under recognized exceptions to the hierarchy of courts doctrine.

In early 2021, the national government announced plans to procure and distribute Sinovac vaccines to address the COVID-19 pandemic. The petitioner, a former local official, raised concerns regarding the vaccine’s efficacy and the absence of locally conducted clinical trials prior to its distribution and use. The government proceeded with procurement under emergency authorizations, relying on international health agency recommendations and legislative exemptions from standard regulatory and procurement procedures. The petitioner filed the instant petition directly before the Supreme Court to halt the procurement and mandate compliance with standard FDA trial and procurement rules.

• Petitioner Pedrito M. Nepomuceno filed a petition for writ of mandamus against President Rodrigo Duterte, DOH Secretary Francisco Duque, the Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID), and Gen. Carlito Galvez, Jr. (Ret.).
• Petitioner sought to compel respondents to observe FDA rules regarding the acquisition, procurement, and use of drugs, specifically demanding that the Sinovac vaccine undergo clinical trials in the Philippines before receiving emergency or regular use authorization.
• Petitioner further prayed for a cease-and-desist order against the purchase and use of the Sinovac vaccine and for the application of standard public bidding requirements in its procurement.
• The petition was grounded on reports questioning the Sinovac vaccine’s efficacy and the absence of concrete local studies on its effectiveness against SARS-CoV-2.
• At the time of the petition, Congress had enacted Republic Act No. 11494 (Bayanihan to Recover as One Act) and Republic Act No. 11525 (COVID-19 Vaccination Program Act of 2021), which expressly waived Phase IV clinical trial requirements and authorized negotiated procurement for COVID-19 vaccines.
• Executive Order No. 121 authorized the FDA Director-General to issue Emergency Use Authorizations (EUAs) for COVID-19 vaccines based on international standards and available clinical data.
• The FDA granted an EUA for the Sinovac vaccine on February 22, 2021, after evaluating data from foreign clinical trials and approvals from counterpart regulatory authorities.

• Petitioner maintained that the government’s procurement and administration of the Sinovac vaccine violated FDA rules requiring clinical trials prior to drug authorization.
• Petitioner argued that respondents unlawfully neglected their ministerial duty to ensure vaccine safety and efficacy through local clinical trials before distribution.
• Petitioner further contended that the procurement process failed to observe mandatory public bidding requirements under existing procurement laws, thereby necessitating judicial intervention via mandamus.

• Procedural Issues:
  • Whether the incumbent President is a proper party to be sued in a petition for mandamus during his tenure.
  • Whether the petitioner’s direct resort to the Supreme Court violates the doctrine of hierarchy of courts.
• Substantive Issues:
  • Whether the respondents’ procurement and authorization of the Sinovac vaccine constitute a ministerial duty that can be compelled through a writ of mandamus.
  • Whether existing laws and executive issuances exempt the government from mandatory clinical trial and public bidding requirements for COVID-19 vaccines.

• Procedural:
  • The Court dismissed President Duterte as a respondent, holding that an incumbent President enjoys absolute immunity from suit during his tenure, regardless of the nature of the suit or whether the acts complained of are official or personal. This immunity exists to prevent distraction from the discharge of executive duties and is not intended to immunize the President from eventual accountability, which may only be pursued through impeachment.
  • The Court dismissed the petition for improper direct resort, ruling that the challenge to vaccine efficacy presents questions of fact beyond the Supreme Court’s jurisdiction. The Court is not a trier of facts, and the doctrine of hierarchy of courts requires that petitions for mandamus be filed first with the Regional Trial Court. Petitioner failed to demonstrate any special and important reason or purely legal question that would justify an exception to this doctrine.
• Substantive:
  • The Court denied the writ of mandamus, holding that the respondents’ actions in procuring and authorizing COVID-19 vaccines were discretionary, not ministerial. Mandamus only lies to compel acts specifically enjoined by law without the exercise of official judgment.
  • The Court found that Republic Act No. 11494 and Republic Act No. 11525 expressly waived the mandatory clinical trial and public bidding requirements for COVID-19 vaccines, authorizing the President to exercise broad discretion in pandemic response and permitting negotiated procurement under emergency cases. Executive Order No. 121 further empowered the FDA to issue Emergency Use Authorizations based on international health agency recommendations and available clinical data. Consequently, the FDA’s grant of an EUA to the Sinovac vaccine was lawful, and no ministerial duty existed to compel local trials or public bidding.

• Presidential Immunity from Suit — The doctrine holds that an incumbent President is absolutely immune from suit during his tenure, irrespective of the nature of the proceeding or whether the complained acts are official or personal. The Court applied this doctrine to drop President Duterte as a respondent, emphasizing that the immunity is designed to shield the Chief Executive from distraction and harassment, preserving the undivided attention required for executive functions. Accountability remains available through impeachment, not ordinary litigation.
• Doctrine of Hierarchy of Courts — This constitutional imperative requires litigants to file petitions in the appropriate lower courts before resorting to the Supreme Court, particularly when factual determinations are necessary. The Court applied this doctrine to dismiss the petition outright, noting that the Supreme Court is not a trier of facts and that concurrent jurisdiction over mandamus does not grant unrestricted freedom to bypass the Regional Trial Court absent purely legal questions or recognized exceptions.
• Ministerial vs. Discretionary Duty (Mandamus) — Mandamus only compels the performance of a ministerial duty, defined as an act performed in obedience to legal mandate without the exercise of official judgment or discretion. The Court applied this distinction to hold that vaccine procurement and EUA issuance involve policy discretion and statutory exemptions, rendering mandamus an inappropriate remedy.

• "The rationale for the grant to the President of the privilege of immunity from suit is to assure the exercise of Presidential duties and functions free from any hindrance of distraction, considering that being the Chief Executive of the Government is a job that, aside from requiring all of the office-holder's time, also demands undivided attention." — The Court invoked this principle from Soliven v. Makasiar to justify the absolute nature of presidential immunity during tenure, emphasizing that requiring the President to personally invoke immunity case-by-case would defeat its very purpose and subject the office to deluges of litigation.
• "Extraordinary times that present an invisible threat to the health of individuals, unbeknown to humanity, require an immediate exceptional response from the government." — The Court used this statement to contextualize the legislative waivers of clinical trial and bidding requirements, underscoring that emergency statutes validly confer broad executive discretion to expedite pandemic response measures aligned with international health standards.

• De Lima v. President Duterte (G.R. No. 227635, October 15, 2019) — Cited as controlling precedent establishing that presidential immunity from suit is absolute during tenure and applies regardless of the nature of the action or whether the acts are official or personal.
• Soliven v. Makasiar — Cited to define the rationale behind presidential immunity, emphasizing that the privilege exists to prevent distraction from executive duties and must be invoked by the President himself, though the Court clarified that requiring such invocation would defeat the immunity's protective purpose.
• David v. Macapagal-Arroyo — Cited to reinforce that presidential immunity preserves the dignity of the office and prevents harassment, while clarifying that accountability is preserved through impeachment, not civil or administrative suits during tenure.
• Philippine Coconut Authority v. Primex Coco Products, Inc. — Cited to delineate the boundary between ministerial and discretionary acts, establishing that mandamus only lies to compel ministerial duties and cannot be used to control the exercise of official judgment.
• Gios-Samar Inc. v. Department of Transportation and Communications — Cited to expound on the doctrine of hierarchy of courts, emphasizing that direct resort to the Supreme Court is improper absent special and important reasons involving purely legal questions, and that bypassing lower courts deprives litigants of due process.

• Section 3, Rule 65 of the Revised Rules of Court — Cited as the governing procedural rule for petitions for mandamus, establishing that the writ only lies when a public officer unlawfully neglects a ministerial duty specifically enjoined by law.
• Article VII, Section 23(2) of the 1987 Constitution — Cited as the constitutional basis for Congress delegating emergency powers to the President under Republic Act No. 11494 to address the pandemic.
• Republic Act No. 11494 (Bayanihan to Recover as One Act), Sections 4 and 12 — Cited as the statutory authority granting the President broad discretion to implement pandemic response measures and expressly waiving Phase IV clinical trial requirements for COVID-19 vaccines.
• Executive Order No. 121 — Cited as the executive issuance authorizing the FDA to grant Emergency Use Authorizations for COVID-19 vaccines based on international standards and available clinical data, precluding the need for local trials.
• Republic Act No. 11525 (COVID-19 Vaccination Program Act of 2021), Section 3 — Cited to demonstrate that Congress explicitly authorized negotiated procurement for COVID-19 vaccines, exempting them from standard public bidding requirements under R.A. 9184.
• Section 21, B.P. Blg. 129 — Cited to establish the concurrent original jurisdiction of Regional Trial Courts over petitions for mandamus, reinforcing the hierarchy of courts doctrine.